Tuberculosis Diagnostics - Global Strategic Business Report

The global market for Tuberculosis Diagnostics was valued at US$2.2 Billion in 2024 and is projected to reach US$2.6 Billion by 2030, growing at a CAGR of 2.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Tuberculosis Diagnostics market.

Global Tuberculosis Diagnostics Market - Key Trends & Drivers Summarized

Why Is Tuberculosis Still a Diagnostic Challenge in the 21st Century?

Despite being a preventable and curable disease, tuberculosis (TB) continues to pose a major public health challenge, especially in low- and middle-income countries. One of the biggest hurdles in the global fight against TB is the timely and accurate diagnosis of the disease, particularly among vulnerable populations such as children, people living with HIV, and individuals in remote or under-resourced areas. Traditional methods like sputum smear microscopy, though widely used, suffer from low sensitivity, especially in cases of extrapulmonary and latent TB. Moreover, the long turnaround time associated with culture methods and the limitations in infrastructure and skilled personnel in many endemic regions make advanced diagnostic solutions difficult to implement at scale. TB's variable clinical manifestations and similarities with other respiratory illnesses further complicate diagnosis, often leading to misdiagnosis or delayed treatment. These limitations underscore the urgent need for faster, more accurate, and accessible diagnostic technologies to help bridge the gap between infection and intervention.

How Are New Technologies Disrupting the Diagnostic Landscape for TB?

Recent years have seen an explosion in diagnostic innovations aimed at making TB detection faster, more accurate, and accessible. Molecular diagnostic tools, particularly nucleic acid amplification tests (NAATs) like GeneXpert and Truenat, have significantly improved the ability to detect TB and multidrug-resistant TB (MDR-TB) within hours. These point-of-care technologies are being deployed in field clinics and rural health centers, where they allow for rapid diagnosis without the need for complex lab infrastructure. In addition to NAATs, other breakthroughs such as interferon-gamma release assays (IGRAs) and TB LAM antigen tests are expanding diagnostic options, especially for people with HIV or in pediatric settings. Artificial intelligence is also being applied to enhance chest X-ray interpretation, while digital diagnostic platforms are improving sample tracking, data recording, and epidemiological mapping. The convergence of diagnostics with mobile health solutions enables remote consultations, follow-ups, and centralized decision-making, particularly valuable in countries with high TB burdens and fragmented healthcare systems.

Is the Global Push for Universal Health Coverage Influencing TB Diagnostic Access?

The global movement toward Universal Health Coverage (UHC) and the United Nations' End TB Strategy are exerting pressure on governments and international agencies to improve diagnostic access as a fundamental step toward eradication. Multilateral organizations like the WHO, Global Fund, and UNITAID are actively funding diagnostic tool development, procurement, and distribution, with a focus on affordability and scalability. National TB programs are being urged to integrate rapid molecular diagnostics into primary healthcare centers, making early detection more feasible and decentralized. In parallel, public-private partnerships are emerging to develop affordable diagnostic kits and local manufacturing capacities to overcome supply chain bottlenecks. However, diagnostic equity remains a challenge, with urban-rural disparities and affordability issues limiting reach. Some governments are adopting integrated disease testing platforms that combine TB testing with HIV, COVID-19, and hepatitis screening, which not only enhances detection but also improves healthcare system efficiency. These multi-disease testing frameworks are expected to drive increased uptake of TB diagnostics across high-risk populations.

What Is Driving Growth in the Tuberculosis Diagnostics Market?

The growth in the tuberculosis diagnostics market is driven by several factors, including the rising global TB incidence in densely populated and high-risk regions, increasing public health investments in infectious disease management, and rapid adoption of molecular diagnostic tools. End-use behavior, such as a growing preference for point-of-care testing in community clinics and mobile health units, is pushing the demand for portable, rapid diagnostics. Additionally, the emergence of drug-resistant TB strains has led to increased adoption of advanced molecular platforms capable of detecting resistance markers alongside TB pathogens. Funding from global health bodies and national governments is also accelerating the deployment of diagnostic tools, especially in endemic countries in Africa, Southeast Asia, and Eastern Europe. Technological trends such as multiplex testing, sample pooling, and automated result interpretation are further enhancing operational scalability. Consumer behavior is also shifting, with heightened awareness about TB symptoms and testing avenues post-COVID, making individuals more proactive in seeking early diagnosis - a factor that will continue to fuel diagnostic volumes globally.

Report Scope

The report analyzes the Tuberculosis Diagnostics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Type (Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis, Other Types); End-Use (Hospitals, Diagnostic Labs, Other End-Uses).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Culture based Diagnosis segment, which is expected to reach US$1.1 Billion by 2030 with a CAGR of a 1.9%. The Sputum Test segment is also set to grow at 3.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $601.4 Million in 2024, and China, forecasted to grow at an impressive 5.1% CAGR to reach $500.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Tuberculosis Diagnostics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Tuberculosis Diagnostics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Tuberculosis Diagnostics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, AdvaCare Pharma, Becton, Dickinson and Company (BD), bioMérieux SA, Cepheid (Danaher Corporation) and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Tuberculosis Diagnostics market report include:

• Abbott Laboratories
• AdvaCare Pharma
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Cepheid (Danaher Corporation)
• DiaSorin S.p.A.
• FIND (Foundation for Innovative New Diagnostics)
• F. Hoffmann-La Roche AG
• Hain Lifescience GmbH
• Hologic, Inc.
• JN-International Medical Corporation
• Lionex GmbH
• Lupin Limited
• Novosibirsk TB Research Institute
• Oxford Immunotec Ltd.
• QIAGEN N.V.
• R-Biopharm AG
• Serum Institute of India Pvt. Ltd.
• Thermo Fisher Scientific Inc.
• Trivitron Healthcare

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry